Clinical pharmacogenetics implementation consortium guideline (CPIC) for <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and dosing of tricyclic antidepressants: 2016 update

Hicks, JK; Sangkuhl, Katrin; Swen, JJ; Ellingrod, VL; Dj, Müller; Shimoda, Kazutaka; Bishop, JR; D Kharasch, E; Skaar, TC; Gaedigk, Andrea; M. Dunnenberger, Henry; E. Klein, Teri; Caudle, KE; Stingl, Julia

doi:10.1002/cpt.597

Public

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Published in Clinical Pharmacology & Therapeutics • Dec 20, 2016

Authors:

JK Hicks

Katrin Sangkuhl

JJ Swen

Abstract

CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimi...

Subject

Dosing

Pharmacogenetics

Guideline

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!